Journal of the Endocrine Society · 2017 · 72 citations · 36 references
MedicineGynecologyPharmacotherapyPain ManagementPain MedicineWomen's HealthAdjuvant AnalgesicsAnalgesiaContraceptive PharmacotherapyEndometriosisMenopause PharmacotherapyPain OutcomesAdjuvant UseEndometriosis PainEndometriosis-related PainMann - Whitney U TestPain ScoresPlacebo ComparatorsRandomization List Management
CONTEXT: Resveratrol has been used for the treatment of endometriosis. OBJECTIVE: To compare resveratrol (40 mg/d) with monophasic contraceptive pill (COC) to COC with placebo for the reduction of pain scores. DESIGN: A randomized clinical trial. SETTING: University Hospital. PATIENTS: Women (ages 20 to 50) with laparoscopic diagnosis of endometriosis were eligible for the study. Exclusion criteria: pregnancy, allergy to resveratrol, or contraindications to COC, use of agonists of gonadotropin release hormone or danazol in the last month, or had used depot medroxyprogesterone acetate or Mirena®. INTERVENTION: Subjects were randomized using a computer-generated randomization list to receive COC for 42 days to be taken with identical capsules containing 40 mg of resveratrol or placebo in coded bottles (1:1 ratio). Allocation was concealed in coded, sequenced, opaque-sealed envelopes. MAIN OUTCOME: Median pain scores measured with a visual analog scale on day 42. RESULTS: test). Median (95% CI) difference between groups was 0.75 (-1.6 to 2.3). CONCLUSION: Resveratrol is not superior to placebo for treatment of pain in endometriosis.
36
ESHRE guideline: management of women with endometriosis
G.A.J. Dunselman, Nathalie Vermeulen, Christian M. Becker et al. · Human Reproduction · 2014 · 2.2K citations · Full text
Medicine, Gynecology, Obstetrics +16
Medical-eligibility criteria for contraceptive use
John Guillebaud · The Lancet · 2001 · 1.1K citations